Evidence map›Paper›PMID 38855752›Full record

ReviewFrontiers in pharmacology2024

Phytotherapeutic options for the treatment of epilepsy: pharmacology, targets, and mechanism of action.

Abdul Waris, Ata Ullah, Muhammad Asim, Rafi Ullah, Md Rafe Rajdoula, Stephen Temitayo Bello, Fahad A Alhumaydhi

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Nutrients · 2026
    Article
  4. Article
  5. Review
  6. Frontiers in pharmacology · 2025
    Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abdul WarisDepartment of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong SAR, China.
Ata UllahDepartment of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong SAR, China.
Muhammad AsimDepartment of Neurosciences, City University of Hong Kong, Kowloon, Hong Kong SAR, China.
Rafi UllahDepartment of Botany, Bacha Khan University Charsadda, Charsadda, Pakistan.
Md Rafe RajdoulaDepartment of Neurosciences, City University of Hong Kong, Kowloon, Hong Kong SAR, China.
Stephen Temitayo BelloDepartment of Neurosciences, City University of Hong Kong, Kowloon, Hong Kong SAR, China.
Fahad A AlhumaydhiDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy is one of the most common, severe, chronic, potentially life-shortening neurological disorders, characterized by a persisting predisposition to generate seizures. It affects more than 60 million individuals globally, which is one of the major burdens in seizure-related mortality, comorbidities, disabilities, and cost. Different treatment options have been used for the management of epilepsy. More than 30 drugs have been approved by the US FDA against epilepsy. However, one-quarter of epileptic individuals still show resistance to the current medications. About 90% of individuals in low and middle-income countries do not have access to the current medication. In these countries, plant extracts have been used to treat various diseases, including epilepsy. These medicinal plants have high therapeutic value and contain valuable phytochemicals with diverse biomedical applications. Epilepsy is a multifactorial disease, and therefore, multitarget approaches such as plant extracts or extracted phytochemicals are needed, which can target multiple pathways. Numerous plant extracts and phytochemicals have been shown to treat epilepsy in various animal models by targeting various receptors, enzymes, and metabolic pathways. These extracts and phytochemicals could be used for the treatment of epilepsy in humans in the future; however, further research is needed to study the exact mechanism of action, toxicity, and dosage to reduce their side effects. In this narrative review, we comprehensively summarized the extracts of various plant species and purified phytochemicals isolated from plants, their targets and mechanism of action, and dosage used in various animal models against epilepsy.

Indexed as

antagonist, agonistanticonvulsiveantiepilepticepilepsyphytochemicalsplant extracts

Identifiers

PMID38855752
PMCPMC11160429

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.